|
|
|
|
||
RVX-297 was comparable or superior to that of the S1P1 agonist FTY720 (fingolimod), 2017?Cytokine Storms https://clinicaltrials.gov/ct2/show/NCT04280588 http://molpharm.aspetjournals.org/content/92/6/694 RVX-297 suppressed EAE pathology when administered to mice either prophylactically or therapeutically. In addition, the production of multiple cytokines in vivo (Fig. 7) and ex vivo (Table 6) was suppressed by RVX-297. In vivo efficacy was comparable or superior to that of the S1P1 agonist FTY720 (fingolimod), an approved therapeutic agent for the treatment of MS. http://molpharm.aspetjournals.org/content/92/6/694 RVX-297 suppressed EAE pathology when administered to mice either prophylactically or therapeutically. In addition, the production of multiple cytokines in vivo (Fig. 7) and ex vivo (Table 6) was suppressed by RVX-297. In vivo efficacy was comparable or superior to that of the S1P1 agonist FTY720 (fingolimod), an approved therapeutic agent for the treatment of MS. |
return to message board, top of board |